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ABSTRACT The human class II gene, HLA-DRa, contains
an octanucleotide sequence ATTTGCAT located %4O base
pairs upstream of the transcription initiation site. We have
investigated the transcriptional function of the DRaoctamer in
human B-lymphoblastoid cells and non-B cells. Deletion and
substitution mutagenesis of the octamer sequence greatly re-
duced the activity of the DRa promoter in both in vivo and in
vitro cell-free transcription systems of B-cell origin. Con-
versely, these mutations did not affect promoter activity in
several non-B-cell lines that express the DRa gene. Removal of
octamer-binding proteins by in vivo titration with an octamer-
containing competitor plasmid reduced DRa promoter activity
in B-lymphoblastoid cells. These results suggest that a protein-
octamer interaction, most likely involving the B-cell-specific
octamer binding protein (OTF-2), is required for DRa pro-
moter function in B-lymphoblastoid cells but not in non-B cells.
The promoter regions of class II major histocompatibility
complex genes contain several DNA sequence motifs, which
probably function as transcriptional regulatory elements.
These include the class II box consensus sequences (1) in
addition to the canonical CCAAT and TATA boxes. The
human class II gene, HLA-DRa, also contains an octanucle-
otide sequence (ATTTGCAT) located -40 base pairs (bp)
upstream of the transcription initiation site. This octamer
motif is an essential transcriptional regulatory element in a
wide variety of eukaryotic promoters, including immuno-
globulin light- and heavy-chain gene promoters (2, 3). The
HLA-DRa gene may be unique among class II genes, in that
the octamer motif is not found in the promoters of any other
human or murine class II genes sequenced to date. The
murine Ea gene does contain a similar sequence (CTTTG-
GAT) at a location identical to the HLA-DRa octamer
sequence.
DNA regulatory elements in eukaryotic promoters act as
binding sites for proteins, and the interaction of these pro-
teins with their target sequences and with each other deter-
mines promoter activity. At least two proteins that specifi-
cally recognize the octamer motif have been identified in
nuclear extracts of mammalian cells. OTF-1 (NF-AI,
OBP100, NF III) is a ubiquitous protein (4-7) that has been
shown to regulate the cell-cycle expression of a human
histone H2B gene (4). OTF-2 (NF-A2, OTF-2A) is a lym-
phoid-specific octamer-binding protein that may account for
the B-cell-specific activity of immunoglobulin promoters
(8-11). We have previously demonstrated that two nuclear
proteins similar to OTF-1 and OTF-2 bind specifically to the
octamer motif in the DRa gene (12).
Since in vitro binding of a protein to DNA does not
necessarily signify an in vivo transcriptional function for that
protein, we have taken several experimental approaches to
demonstrate that the octamer does function as a transcrip-
tional regulatory element in the HLA-DRa promoter. These
include deletion and substitution mutational analysis, in vivo
competition assays, and in vitro transcriptional analysis.
Using these approaches, we have determined that the oc-
tamer is crucial for DRa gene expression in B cells but is
dispensable for its expression in non-B cells.
MATERIALS AND METHODS
Cell Lines. Raji is a human Epstein-Barr virus-positive
Burkitt lymphoma cell line. Namalwa is a B-lymphoblastoid
cell line. Sk-Mel13 (ref. 13; provided by A. Houghton,
Sloan-Kettering) and Du-Mell7 (ref. 14; provided by M.
Carrington and F. Ward, Duke University) are DR-
expressing melonoma lines. U373MG and U105MG are DR-
expressing glioblastoma lines (15).
DNA Constructs. Deletion mutants 5'A-109, 5'A-56, and
5'A-43 containing 5' flanking sequences of the HLA-DRa
gene fused to the bacterial chloramphenicol acetyltransferase
(CAT) gene are described in detail in ref. 12 (see Fig. 1). In
5'A-109, the conserved class II boxes (X+Y), the octamer,
and all downstream regulatory elements through the cap site
are present. In 5'A-56, the class II boxes are deleted but the
octamer and all downstream regulatory elements including
the cap site are present; in 5'A-43, the octamer is further
deleted. 5'A-56X+Y is a reconstructed plasmid that contains
the class II boxes and the octamer. It was obtained by
linearizing 5'A-56 with Xba I; this was followed by treatment
with Klenow enzyme to form blunt ends and insertion of a
single copy of a 50-bp oligonucleotide containing the X and
Y consensus sequences. 5'A-43X+Y is a reconstructed plas-
mid that contains the class II boxes but lacks the octamer
element. It was prepared in an identical fashion to 5'A-
56X+Y, except that the starting plasmid was 5'A-43.
Constructs containing substitution mutations in the oc-
tamer were obtained by inserting a single copy of a 74-bp
oligonucleotide containing the class II boxes and either the
Ea octamer-like sequence (CTTTGQAT, underlined nucle-
otides differ from the DRa octamer) or a second mutated
octamer sequence (CGGGTCAT) into linearized 5'A-43. The
latter mutations were chosen to conserve the trinucleotide
CAT at the 3' end of the octamer, which in one report has
been designated as a putative CCAAT box (16). These
Abbreviations: CAT, chloramphenicol acetyltransferase; MHC, ma-
jor histocompatibility complex.
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constructs were called, respectively, pEaoct and pMUToct.
Finally, a parallel construct (designated pWToct) containing
the wild-type octamer sequence was prepared by inserting a
74-bp oligonucleotide containing the class II boxes and the
wild-type octamer (A1TTGCAT) into 5'A-43. As shown in
Fig. 1, pWToct is equivalent to 5'A-56X+Y, except for some
sequence differences resulting from the cloning operations in
the region between the Y box and the octamer (addition ofan
Xba I linker and deletion of the sequence AGTA in 5'A-
56X+Y), and in the region between the octamer and the
TATA box (addition of an Xba I linker and duplication of the
sequence TTAATGG in pWToct). Constructs were charac-
terized by dideoxynucleotide DNA sequence determination
directly from the double-stranded plasmid DNA (17), using a
20-base oligonucleotide complementary to nucleotides 15-34
of the coding sequence of the CAT gene (18) as a primer for
reverse transcriptase. pD164-2, the parental plasmid for all of
the DRa-CAT recombinants, does not contain any DRa
sequences (19).
pH2bl-12 contains the human histone H2B sequences from
-54 to +117 inserted into the Sma I site of puc13. pH2b-
OMA is an octamer double-point mutant containing the H2B
sequences from -59 to + 128, in which the sequence ATT-
TGCAT (-49 to -42) was mutated to AaTTGAAT (20).
pGEM-4CPE was obtained by subcloning a Pst I/EcoRI
fragment containing H2B sequences from +230 to -151 (20)
between the EcoRI and Pst I sites of pGEM-1.
For in vivo competition studies, a 24-bp oligonucleotide
containing the octamer motifflanked by sequences unrelated
to the DRa gene was inserted into the Sma I site of pUC18.
Trandection. All cells were transiently transfected by using
a Bio-Rad Gene Pulser electroporation apparatus. Cells (106)
were collected by centrifugation and resuspended in 0.3 ml of
complete RPMI medium. The cell suspension was then
placed into the electroporation chamber; this was followed by
addition ofDNA, mixing, and application ofthe voltage pulse
(200 V, 960 ,uF). The cells were immediately transferred to 10
ml of complete RPMI medium. Approximately 48 hr after
transfection, cells were counted, harvested by centrifuga-
tion, washed once with phosphate-buffered saline, and re-
suspended in 0.25 M Tris-HCl (pH 7.6) (50 ul per 106 cells).
Cells were lysed by several freeze-thaw cycles, cellular
debris was removed by centrifugation, and the resulting
extracts were assayed for CAT activity as described (21).
Preparation of Nuclear Extracts for in Vitro Cell-Free Tran-
scription. Namalwa cells were grown in spinner flasks in
RPMI 1640 medium supplemented with nonessential amino
acids, glutamine, and 10% fetal bovine serum. HeLa cells
were grown in spinner flasks in Joklik's minimal essential
medium supplemented with 5% calf serum. Cells were har-
vested at 2 x 106 cells per ml and nuclear extracts were
prepared as described (22), except that Tris was substituted
for Hepes.
In Vitro Cell-Free Transcription. Transcription reaction
mixtures (25 A.1) contained 20mM Tris-HCl (pH 8.0), 100mM
KCl, 3 mM MgCl2, 0.75 mM ribonucleoside triphosphates,
0.5 pg of supercoiled template DNA, and 10 p1(=80 pg of
protein) of Namalwa or HeLa extracts. Transcription was
carried out for 1 hr at 30°C; this was followed by digestion
with RNase-free DNase I to destroy the template DNA. In
vitro transcribed RNAs from DRa-CAT templates were
mapped by primer-extension analysis as follows. The primer,
a 20-base oligonucleotide complementary to nucleotides 15-
34 of the coding sequence of the CAT gene (18), was
end-labeled with l-o32P]ATP and T4 polynucleotide kinase.
RNA plus 4 pmol of primer were ethanol precipitated,
resuspended in 3 ,u1 of 10 mM Tris-HCl, pH 8.0/1 mM EDTA,
and incubated at 70°C for 5 min. Two microliters of 250 mM
Tris-HCl, pH 8.0/250mM KCl/200mM dithiothreitol/40mM
MgCl2 was added, and the samples were incubated at 42°C for
1 hr. This was followed by incubation for 30 min at 42°C in
the presence of 1 mM deoxynucleoside triphosphates and 20
units of avian myeloblastosis virus reverse transcriptase
(total reaction vol, 10 p.1). Products were purified by ethanol
precipitation and analyzed on an 8% denaturing polyacryl-
amide gel. In vitro synthesized RNAs from H2B templates
were mapped by RNase protection analysis (23), using an SP6
probe derived from pGEM-4CPE cut with EcoRI.
RESULTS
Deletion and Substitution Mutagenesis of the Octamer Se-
quence Reduces HLA-DRa Promoter Activity in B-Lympho-
blastoid Cells but Not in DR-Expressing Glioblastomas and
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FIG. 1. The promoter region of the HLA-DRa gene. Nucleotides are numbered relative to the cap site. Potential cis-acting regulatory
elements include the class II boxes (X and Y), the octamer sequence, and a TATA box. A CCAAT box is located on the opposite strand of
the Y consensus sequence. 5' deletion mutants contained DRa sequence extending from positions indicated by the arrows above the sequence
to +30. Differences (indicated by brackets) between 5'A-56X+Y and pWToct are also shown above the parental sequence. The 50-bp
oligonucleotide (contains the class II boxes) and the 74-bp oligonucleotide (contains the class II boxes and the octamer) used in promoter
reconstructions are shown below the sequence.
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class II boxes, the octamer, and theTATA box (Fig. 1). When
fused to the CAT gene, these DNA sequences can function
as a tissue-specific promoter (12, 24). We investigated the
contribution of the octamer to DRa promoter activity by
altering selected bases of this sequence or by completely
removing it. Octamer deletion and substitution mutants were
prepared by a promoter reconstruction strategy, which in-
volved inserting oligonucleotides containing the desired
changes into an Xba I restriction site created at the 5' end of
a DRa-CAT recombinant 5'A-43 (a deletion mutant in which
DRa 5' flanking sequences through the octamer were re-
moved). These constructs were introduced by electropora-
tion into a B-lymphoblastoid cell line, Raji, that constitutively
expresses high levels of the HLA-DR antigen. The results of
the transient transfection analyses are given in Tables 1 and
2. Both deletion (Table 1) and substitution mutagenesis
(Table 2) of the octamer sequence reduced DRa promoter
activity in Raji cells by 80-90o. Interestingly, the octamer-
like sequence from the Ea gene promoter could not substitute
for the DRa octamer in our system.
In contrast to the observations with Raji cells, neither
deletion nor substitution mutations in the octamer sequence
decreased CAT gene expression in DR-expressing non-B-cell
lines. This was consistently demonstrated in melanoma and
glioblastoma lines (Tables 1 and 2).
Titration of Octamer-Binding Proteins Reduces HLA-DRa
Promoter Activity in Raji Cefls. We used an in vivo compe-
tition assay to further define the role of the octamer sequence
in the DRa promoter. In this approach, sequence-specific
regulatory proteins that are present in limiting amounts in the
cell are titrated by introducing a large excess of DNA
containing the binding sequence of interest (25). If protein
binding to the octamer sequence activates the HLA-DRa
gene promoter, titration of octamer-binding proteins should
reduce promoter activity. The results of an in vivo competi-
tion assay in which increasing amounts of a plasmid contain-
ing the octamer sequence were cotransfected with a DRa-
CAT recombinant are shown in Fig. 2. CAT expression from
the DRa promoter was considerably reduced by increasing
quantities ofthe competitor plasmid. The octamer-containing
Table 1. Analysis of HLA-DRa octamer deletion mutants in Raji
cells, melanomas, and a glioblastoma line
Relative CAT
Cell type No. of exp. Plasmids activity
Raji 3 5'A&-56X+Y 1.00 (14.8%)
(B cells) 5'A-43X+Y 0.23 ± 0.10
5'A-56 0.20 ± 0.04
5'A-43 0.16 ± 0.09
Sk-Mell3 2 5'A-56X+Y 1.00 (10.7%)
(melanoma) 5'A-43X+Y 1.21 ± 0.20
pD164-2 0.06 ± 0.01
Du-Mell7 3 5'A-56X+Y 1.00 (2.6%)
(melanoma) 5'A-43X+Y 1.50 ± 0.20
pD164-2 0.15 ± 0.02
U105MG 2 5'A-56X+Y 1.00 (63%)
(glioblastoma) 5'A-43X+Y 0.84 ± 0.01
pD164-2 0.31 ± 0.07
5'A-56X+Y is a reconstructed plasmid that contains the class II
boxes (X+Y), the octamer element, and DRa sequence 3' to the
octamer element. In 5'A-43X+Y, the octamer element is deleted.
pD164-2 is identical to the above two plasmids except it lacks allDRa
5' sequences. Raji cells were transfected with octamer deletion and
substitution mutants. Extracts of transfected cells were analyzed for
CAT activity by TLC and autoradiography. Conversion of chloram-
phenicol to its acetylated forms was quantified by cutting out and
counting sections of the TLC plates. Data for deletion mutants and
pD164-2 were normalized to CAT activity measured for 5'A-56X+Y;
data for substitution mutants were normalized to pWToct. The
average percent acetylation is given in parentheses.
Table 2. Analysis of HLA-DRa octamer substitution mutants in
Raji cells, melanomas, and glioblastomas
Transfected Relative CAT
Cell type No. of exp. plasmids activity
Raji 2 pWToct 1.00 (16.9%)
(B cells) pEaoct 0.12 ± 0.03
pMUToct 0.10 ± 0.01
5'A-43 0.10 ± 0.03
Sk-Mell3 4 pWToct 1.00 (4.4%)
(melanoma) pMUToct 1.55 ± 0.25
pD164-2 0.13 ± 0.03
Du-Mell7 3 pWToct 1.00 (3.2%)
(melanoma) pMUToct 1.18 ± 0.40
pD164-2 0.18 ± 0.04
U373MG 2 pWToct 1.00 (3.15%)
(glioblastoma) pMUToct 0.89 ± 0.04
pD164-2 0.23 ± 0.07
U1O5MG 4 pWToct 1.00 (90%o)
(glioblastoma) pMUToct 1.60 ± 0.36
pD164-2 0.16 ± 0.07
pWToct is a reconstructed plasmid that contains the class II boxes
(X+Y), the octamer element and DRa sequences 3' to the octamer
element. pEaoct and pMUToct were prepared in an identical fashion
to pWToct except an Ea octamer or a mutated octamer, respectively,
were used in place of the wild-type octamer. See Table 1 legend and
Materials and Methods for information on the other plasmids; see
Table 1 legend for CAT activity data.
oligonucleotide that was used in the competitor plasmid also
competed for protein binding to the DRa octamer in an
electrophoretic mobility shift assay (data not shown). This
result lends support to the conclusion that the octamer is an
important functional element of the HLA-DRa promoter in B
cells. In addition, the function ofthis element is dependent on
its interaction with a trans-acting molecule.
The Octamer Sequence in theDRa Promoter Is Required for
in Vitro Transcription in a B-Cell Extract. The in vivo tran-
scription results described above were complemented and
extended by analyzing the function of the DRa octamer in an
in vitro cell-free transcription system. Nuclear extracts that
accurately and efficiently transcribed from RNA polymerase
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FIG. 2. In vivo competition analysis. Increasing amounts of a
competitor plasmid containing the octamer sequence were cotrans-
fected into Raji cells with 2 pg of 5'A-109 (DRa-CAT recombinant).
Plasmid pUC 7 was added as indicated to yield a total of 32 Ug of
DNA per transfection. Forty-eight hours posttransfection, cell ex-
tracts were analyzed for CAT activity. Enzyme activity was calcu-
lated as the percentage of chloramphenicol converted to the acety-
lated forms and was normalized to the activity measured for 5'A-109
(100%1 relative CAT activity). Values from quadruplicate transfec-
tions were averaged.
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FIG. 3. In vitro transcriptional activity of the HLA-DRa pro-
moter and the H2B promoter. (A) Autoradiograph of an 8% dena-
turing polyacrylamide gel of CAT RNA transcribed from the DRa
promoter and mapped by primer-extension analysis. Transcripts
correctly initiated at the DRa cap site are indicated by an arrow. The
templates for transcription were 5'A-56X+Y (wild-type octamer,
lanes 1 and 3), 5'A-43X+Y (octamer deletion mutant, lanes 2 and 4),
pWToct (lanes 5 and 7), and pMUToct (octamer with a 5-base
mutation) (lanes 6 and 8). DNA constructs are described in detail in
Materials and Methods. Lanes 1, 2, 5, and 6, Namalwa nuclear
extract (N); lanes 3, 4, 7, and 8, HeLa nuclear extract (H). (B)
Autoradiograph of H2B transcripts analyzed by RNase protection
mapping. The templates were pH2bl-12 (wild-type octamer, lanes 1
and 3) and pH2b-OMA (double point mutant octamer, lanes 2 and 4).
Protected RNA transcribed from the former construct was 117
nucleotides (nt) as indicated. The latter yielded a weak 128-
nucleotide transcript. Lanes 1 and 2, Namalwa extract; lanes 3 and
4, HeLa extract.
(Namalwa, a human Burkitt lymphoma) and a DR-negative
cell line (HeLa). The Namalwa cell extracts produced one
predominant transcript, correctly initiated at the DRa cap
site, for both 5'A-56X+Y (Fig. 3A, lane 1) and for pWToct
(lane 5). Both of these constructs contain the class II boxes,
the octamer element, and all downstream regulatory se-
quences inclusive of the cap site. Deletion of the octamer
sequence (lane 2) and changing the first 5 bases ofthe octamer
sequence (lane 6) greatly reduced transcription from the DRa
promoter by the Namalwa nuclear extract.
HeLa nuclear extracts exhibited very low transcriptional
activity with constructs containing the wild-type DRa pro-
moter, in accord with the B-cell-specific expression of the
DRa gene (Fig. 3A, lanes 3 and 7). The transcription of a
control template by the HeLa extract was examined to ensure
that this HeLa extract exhibited transcriptional activity. A
construct containing a wild-type histone H2B promoter,
which is not tissue specific, was transcribed equally well by
the Namalwa (Fig. 3B, lane 1) and HeLa (lane 3) nuclear
extracts. The octamer element is required for H2B promoter
function. Accordingly, mutations in the octamer abrogated
the production of correctly initiated transcripts from the H2B
promoter (lanes 2 and 4).
DISCUSSION
In a previous study, we demonstrated by in vitro DNA-
protein binding assays that at least two nuclear proteins bind
specifically to the octamer motif ATl-TGCAT in the DRa
gene (12). One of these proteins is B-cell specific, and the
other is not cell specific. There is some evidence that a
B-cell-specific octamer-binding protein is important in immu-
noglobulin gene regulation (10), while a ubiquitous octamer-
binding protein is involved in the cell-cycle-dependent
expression of the histone H2B gene (4). The class II major
histocompatibility complex (MHC) genes are similar to
immunoglobulin genes in that they are expressed at high
levels in B lymphocytes. In contrast to immunoglobulin
genes, class II MHC genes are also expressed by macro-
phages, some T cells, and in -interferon-treated cells of a
number of other lineages. In this report, we have assessed the
role of the octamer sequence in the expression of the HLA-
DRa gene in a B-lymphoblastoid cell line and several non-
B-cell lines.
The function of the octamer sequence in the DRa promoter
was evaluated in both in vivo transfection and in vitro
cell-free transcription systems. Similar results were obtained
with these two approaches. Deletion and substitution muta-
genesis of the octamer sequence resulted in a large reduction
in promoter activity in B cells. Although these data do not
exclude the possibility that additional DNA regulatory ele-
ments, upstream or downstream ofthe octamer sequence, are
important for the B-cell-specific expression of the HLA-DRa
gene, it does establish that the octamer motif is a positive
transcriptional regulatory element in B cells. Importantly,
mutations in the octamer sequence did not affect indicator
(CAT) gene expression in DRa-expressing cells of glioblas-
toma and melanoma lineages. This observation supports the
hypothesis that diverse, cell-specific regulatory pathways are
involved in the expression of class II MHC genes. It is
noteworthy that other studies with somatic hybrids have
reached a similar conclusion (26).
In addition to establishing the function of the octamer
sequence in the DRa gene, the functional role of protein
binding to this sequence was assessed. It is generally ac-
cepted that cis-acting DNA regulatory elements control gene
transcription via their interaction with trans-acting factors.
Our data show that removal of octamer-binding proteins by
in vivo titration with an octamer-containing competitor plas-
mid reduces DRa promoter activity in Raji cells, thus pro-
viding evidence that protein-octamer interactions are impor-
tant for DRa gene expression in B cells. The individual
contributions of the B-cell-specific (OTF-2) and the ubiqui-
tous (OTF-1) octamer-binding proteins in DRa gene regula-
tion were not assessed.
Based on the observations in this study, we propose that
B-cell-specific DRa gene expression is regulated in part by
the interaction of OTF-2 with the octamer element. This in
combination with protein-DNA interactions involving other
known regulatory elements of the DRa gene such as the class
II boxes (24) and the W(Z) element (ref. 27; J. Cogswell,
P.V.B., and J.P.-Y.T., unpublished observation) result in
DRa gene expression in B cells. DRa gene expression in
non-B cells is controlled primarily by interactions of nuclear
proteins with these latter regulatory elements. In accord with
this hypothesis, data from our laboratory indicate that the
requirements for the W, X, and Y regions in DRa gene
regulation are similar for all cell types examined (J. Cogswell,
P.V.B., and J.P.-Y.T., unpublished observation). The oc-
tamer element of the DRa gene appears to be dispensable in
non-B cells. This would imply that OTF-1, which is produced
by these cells, does not function in DRa gene control. The
simplest explanations for this are (i) intracellularly, OTF-1
does not bind to the DRa octamer element due to its inability
to interact properly with other regulatory proteins that bind
to DNA elements proximal to the octamer; or (ii) OTF-1
binds to the octamer element, but this binding does not
regulate gene transcription.
It is enigmatic that the octamer sequence plays an impor-
tant role in the B-cell expression of the DRa gene yet the
upstream regions of other class II MHC genes do not contain
this sequence. The murine homologue of the DRa gene, Ea,
contains an octamer-like sequence (CTllGGAT) at a loca-
tion identical to the HLA-DRa sequence. However, the Ea
sequence was not transcriptionally active when it was sub-
stituted for the wild-type octamer in the DRa promoter.
In conclusion, this report provides evidence that the oc-
tamer sequence in the HLA-DRa gene is a positive transcrip-
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tional regulatory element in B cells. Conversely, it appears to
be dispensable for DRa transcription in non-B cells. This
provides the molecular basis for the diverse cell-specific
regulatory pathways that are involved in class II MHC gene
control. The function of the octamer in B lymphocytes is
mediated by interactions with DNA binding molecules, one
ofwhich is likely the B-cell-specific octamer-binding protein.
The availability of isolated octamer-binding proteins, in com-
bination with a homologous cell-free transcription system,
should greatly facilitate our understanding of class II MHC
gene regulation.
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